Susan Goobie: Pediatric Transfusion Rates and Risks Spike
Susan Goobie, Pediatric Anesthesiologist at Boston Children’s Hospital, posted on LinkedIn:
”Our BJA Transfusion Outcomes in Paediatric Surgical Patients (TOPS) study reports that perioperative paediatric red blood cell transfusion trended upward over the past decade, with an overall transfusion rate of 6.3% and of 13.3% in neonates.
The 30-day mortality rate in those transfused was 2.4%, and was 14.9% in neonates, compared with 0.2% in the non-transfusion group.
We report an overall 1.2- to 5.2-fold increased rate of morbidity and 2-fold increased rate of mortality in the cohort exposed to RBC transfusion perioperatively compared with the cohort who did not receive blood.
Which surgical procedures associated with the highest probability of blood transfusion?
Is there an increased risk of infection in the transfused patients?
Does the total transfusion volume matter?
How can patient blood management be used to decrease transfusion exposure in neonates, children and adolescents?
Read our article – free to download for 50 days.”
Title: Transfusion and outcomes in paediatric surgical patients: an 11-year retrospective North American cohort study
Authors: Susan Goobie, David Faraoni

Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia
